---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-010116"
form_type: "8-K"
ticker: "SRPT"
cik: "0000873303"
company_name: "Sarepta Therapeutics, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:59:55.937426+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sarepta preliminary 2025 net product revenue $1.86B; ELEVIDYS $898.7M

## Summary
- Total net product revenue Q4 $369.6M, full-year $1.86B; cash and investments $953.8M at year-end.
- ELEVIDYS revenue Q4 $110.4M (impacted by flu and rescheduled infusions), full-year $898.7M.
- PMO franchise revenue Q4 $259.2M, full-year $965.6M; described as durable.
- CEO reconfirms ELEVIDYS annual sales floor of $500M; more detailed guidance deferred until initiatives evaluated.
- Preliminary results unaudited; final Q4/FY 2025 results expected late February 2026.

## SEC filing metadata
- accession: 0001193125-26-010116
- form_type: 8-K
- ticker: SRPT
- cik: 0000873303
- company_name: Sarepta Therapeutics, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/873303/000119312526010116/0001193125-26-010116-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/873303/000119312526010116/srpt-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-010116
- JSON: https://secwatch.observer/filing/0001193125-26-010116.json
- Plain text: https://secwatch.observer/filing/0001193125-26-010116.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.